Has Lynn Malec, MD received payments from drug or device companies?

Yes. Drug and device makers reported $663,866 in general payments to Lynn Malec, MD across 420 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Lynn Malec, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Lynn Malec, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Lynn Malec, MD

Pediatric Hematology-Oncology · Milwaukee, WINPI 1629222450

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (43.4%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 20 manufacturers reported payments, led by Sanofi at 46.6% of the total. Among pediatric hematology-oncology clinicians in WI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$663,866in general payments, 2019–2025

Across 420 payments — averaging $1580.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Sanofi$310K
CSL Behring$105K
Bioverativ Therapeutics Inc.$44K
Takeda Pharmaceuticals U.S.A., Inc.$43K
Sanofi-aventis U.S. LLC$32K
Genentech USA, Inc.$29K
plus $101K from 14 others

$704,321in research payments, 2019–2025

Across 398 payments — averaging $1769.65 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Sanofi US Services Inc.$457K
Novo Nordisk AS$80K
Sanofi$68K
Biomarin Pharmaceutical Inc.$42K
CSL Behring$27K
Pfizer$22K
plus $8K from 2 others

What the payments were for

Consulting fees$286,68743%
Speaking & faculty fees$287,79043%
Travel & lodging$79,61012%
Food & beverage$9,5741%
Education$1920%
Gifts$120%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Sanofi	147	$309,620
CSL Behring	86	$104,885
Bioverativ Therapeutics Inc.	38	$44,208
Takeda Pharmaceuticals U.S.A., Inc.	23	$42,718
Sanofi-aventis U.S. LLC	12	$31,811
Genentech USA, Inc.	35	$29,149
Swedish Orphan Biovitrum AB	6	$24,106
Sanofi US Services Inc.	2	$23,170
Novo Nordisk	12	$14,476
Biomarin Pharmaceutical Inc.	20	$11,878
Biotest AG	1	$10,817
Pfizer	11	$7,418
Spark Therapeutics, Inc.	2	$4,535
HEMA Biologics, LLC	7	$2,545
Shire North American Group Inc	12	$1,682
Octapharma USA, Inc.	1	$473
Bio Products Laboratory USA, Inc.	1	$172
Astellas Pharma US Inc	1	$72
Kedrion Biopharma, Inc.	2	$71
Bayer	1	$61

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

ALTUVIIIO$72,787
ALPROLIX$66,550
ELOCTATE$62,480
HEMGENIX$54,658
HEMLIBRA$28,109
Idelvion$27,745
ADVATE$8,500
NO PRODUCT DISCUSSED$6,452
Afstyla$6,051
HYMPAVZI$5,750
Roctavian$4,770
VONVENDI$3,208
SevenFact$2,500
QFITLIA$1,504
CABLIVI$1,335
NUWIQ$473
Coagadex$172

How this compares

$663,866 in reported general payments places this provider in the 95th percentile of 46 pediatric hematology-oncology providers in Wisconsin.

See all pediatric hematology-oncology providers in Wisconsin →

Medicare billing

Part B allowed, 2024

$589,652

Medicare patients

Services billed

86,100

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other pediatric hematology-oncology in Milwaukee

Michael BurkeMilwaukee$76K
Brian BranchfordMilwaukee$66K
Thomas AbshireMilwaukee$40K
Veronica FloodMilwaukee$28K
Allison RemikerMilwaukee$12K
Robert MontgomeryMilwaukee$11K
Julie-An TalanoMilwaukee$11K
Sarah RumlerMilwaukee$8K
Paul Harker-MurrayMilwaukee$6K
Richard TowerMilwaukee$4K

See the full list for Wisconsin →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →